Skip to main content
NCBI home page
Heart logoLink to Heart
. 2001 Jun;85(6):e9. doi: 10.1136/heart.85.6.e9

Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management

I The
PMCID: PMC1729757  PMID: 11359763

Abstract

OBJECTIVE—IONA (impact of nicorandil in angina) is a randomised, double blind, placebo controlled trial that will test the hypothesis that nicorandil (target dose of 20 mg twice daily) will reduce the incidence of cardiovascular events in a cohort of men and women with effort angina and additional risk factors.
METHODS—The primary composite end point of the study is coronary heart disease death, non-fatal myocardial infarction or unplanned hospital admission for cardiac chest pain, and the secondary end point is the combined outcome of coronary heart disease death or non-fatal myocardial infarction. Other cardiovascular outcomes and all cause mortality will also be reported.
RESULTS—More than 5000 subjects have been randomised to receive nicorandil or placebo in addition to normal antianginal treatment. The target population, the assessments made, and the management of the trial are described in detail.
CONCLUSIONS—The IONA study has achieved its first aim of randomising more than 5000 high risk subjects with effort angina. Subject follow up will be complete in the third quarter of 2001.


Keywords: stable angina of effort; cardiovascular events; nicorandil

Full Text

The Full Text of this article is available as a PDF (143.5 KB).

Figure 1  .

Figure 1  

Open in a new tab

Visit schedule.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auchampach J. A., Cavero I., Gross G. J. Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol. 1992;20(5):765–771. [PubMed] [Google Scholar]
  2. Chibana T., Nagamine F., Sunagawa R., Oshiro K., Nakada Y., Shimabukuro M., Shinzato T., Murakami K., Mimura G., Sakanashi M. Comparison of the acute hemodynamic and coronary vasodilating effects between nicorandil and glyceryl trinitrate. Arzneimittelforschung. 1991 Jun;41(6):591–594. [PubMed] [Google Scholar]
  3. Dargie H. J., Ford I., Fox K. M. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J. 1996 Jan;17(1):104–112. doi: 10.1093/oxfordjournals.eurheartj.a014668. [DOI] [PubMed] [Google Scholar]
  4. Di Somma S., Liguori V., Petitto M., Carotenuto A., Bokor D., de Divitiis O., de Divitiis M. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther. 1993 Feb;7(1):119–123. doi: 10.1007/BF00878320. [DOI] [PubMed] [Google Scholar]
  5. Döring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol. 1992;20 (Suppl 3):S74–S81. [PubMed] [Google Scholar]
  6. Gandhi M. M. Clinical epidemiology of coronary heart disease in the UK. 1997 Jun 18-Jul 8Br J Hosp Med. 58(1):23–27. [PubMed] [Google Scholar]
  7. Gandhi M. M., Lampe F. C., Wood D. A. Incidence, clinical characteristics, and short-term prognosis of angina pectoris. Br Heart J. 1995 Feb;73(2):193–198. doi: 10.1136/hrt.73.2.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gottlieb S. S., McCarter R. J., Vogel R. A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998 Aug 20;339(8):489–497. doi: 10.1056/NEJM199808203390801. [DOI] [PubMed] [Google Scholar]
  9. Gross G. J., Auchampach J. A. Role of ATP dependent potassium channels in myocardial ischaemia. Cardiovasc Res. 1992 Nov;26(11):1011–1016. doi: 10.1093/cvr/26.11.1011. [DOI] [PubMed] [Google Scholar]
  10. Hughes L. O., Rose E. L., Lahiri A., Raftery E. B. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol. 1990 Sep 15;66(7):679–682. doi: 10.1016/0002-9149(90)91129-t. [DOI] [PubMed] [Google Scholar]
  11. Matsubara T., Minatoguchi S., Matsuo H., Hayakawa K., Segawa T., Matsuno Y., Watanabe S., Arai M., Uno Y., Kawasaki M. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol. 2000 Feb;35(2):345–351. doi: 10.1016/s0735-1097(99)00539-2. [DOI] [PubMed] [Google Scholar]
  12. Meeter K., Kelder J. C., Tijssen J. G., Bucx J. J., Henneman J. A., Kerker J. P., Hugenholtz P. G. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol. 1992;20 (Suppl 3):S59–S66. [PubMed] [Google Scholar]
  13. Patel D. J., Purcell H. J., Fox K. M. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization. Eur Heart J. 1999 Jan;20(1):51–57. doi: 10.1053/euhj.1998.1354. [DOI] [PubMed] [Google Scholar]
  14. Pepine C. J., Cohn P. F., Deedwania P. C., Gibson R. S., Handberg E., Hill J. A., Miller E., Marks R. G., Thadani U. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST) Circulation. 1994 Aug;90(2):762–768. doi: 10.1161/01.cir.90.2.762. [DOI] [PubMed] [Google Scholar]
  15. Rubins H. B., Robins S. J., Collins D., Fye C. L., Anderson J. W., Elam M. B., Faas F. H., Linares E., Schaefer E. J., Schectman G. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 Aug 5;341(6):410–418. doi: 10.1056/NEJM199908053410604. [DOI] [PubMed] [Google Scholar]
  16. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M., Wun C. C. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
  17. Scott C. D., McComb J. M., Dark J. H. Heart rate and late mortality in cardiac transplant recipients. Eur Heart J. 1993 Apr;14(4):530–533. doi: 10.1093/eurheartj/14.4.530. [DOI] [PubMed] [Google Scholar]
  18. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  19. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol. 1989 Jun 20;63(21):18J–24J. doi: 10.1016/0002-9149(89)90200-2. [DOI] [PubMed] [Google Scholar]
  20. Ulvenstam G., Diderholm E., Frithz G., Gudbrandsson T., Hedbäck B., Höglund C., Moelstad P., Perk J., Sverrisson J. T. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol. 1992;20 (Suppl 3):S67–S73. doi: 10.1097/00005344-199206203-00012. [DOI] [PubMed] [Google Scholar]
  21. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145–153. doi: 10.1056/NEJM200001203420301. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES